Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annu...(lyzed using the more recent and rigorous...),Health

"Castration-resistant prostate cancer is a devastating disease with high mortality rates and limited treatment options," said Dr. Scher. "MDV3100 has been well tolerated and early results suggest encouraging anti-tumor activity. Additional data currently being generated will clarify its role as a potential therapy for patients with castration-resistant prostate cancer."

"We continue to be very encouraged by the results with MDV3100 obtained to date," said David Hung, M.D., president and chief executive officer of Medivation. "Analysis of the data showed a dose-dependent effect of MDV3100 on PSA levels, CTC counts and clinical outcomes. We continue to gather longer-term data on these patients and are also exploring higher doses."

Medivation expects to complete the study, and report final top-line results, in 2008. If these results are positive, Medivation expects to seek U.S. Food and Drug Administration agreement to enter a pivotal Phase 3 registration study in castration-resistant prostate cancer.

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer. An estimated 186,320 new cases are expected to be diagnosed in 2008, and approximately 28,660 men are expected to die this year from the disease. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases of the central nervous system and cancers for which there are limited treatment options. Medivation aims to revolutionize the treatment of these diseases and offer hope to critical
'/>"/>